# Table of Contents

## Volume 102, s1: April 2017

### Proceedings

**Session 1: Prevention and diagnosis globally and in the region**

1. National prevention strategies for the control of haemoglobin disorders. A special reference to the countries of the Middle East  
   Michael Angastiniotis, Androulla Eleftheriou

6. Diagnostic dilemmas in the detection of complex haemoglobinopathies  
   Erol Baysal

**Session 2: How I treat and monitor**

12. How I treat and monitor sickle cell disease  
    Wasil Jastaniah

20. How I treat and monitor non-transfusion-dependent thalassaemia  

**Session 3: Addressing emergency problems**

28. Thalassaemia major emergency cases  
    Perla Eleftheriou

30. Challenges in the management of silent cerebral infarct in sickle cell disease  
    Wasil Jastaniah

**Keynote presentation**

32. Thalassaemia and other haemoglobinopathies in the WHO Eastern Mediterranean region  
    Asmus Hammerich, Slim Slama, Karima Gholbzouri

**Session 4: Multidisciplinary care**

35. Endocrine complications in thalassaemia syndromes  
    Farrukh T. Shah

39. Cardiac complications in haemoglobinopathies  
    Dimitrios Farmakis

41. Liver complications in thalassaemia syndromes  
    Farrukh T. Shah

**Session 5: Reference centres and networking. Learning from UE standards**

44. The use of e-Registries in building and upgrading services  
    Michael Angastiniotis, Zinonas Antoniou, E.C. Schiza, Costas P. Pattichis, Christos N. Schizas

49. Experience of thalassaemia care in Saudi Arabia  
    Zakaria M. Al Hawaswi, Mohammed A. Alaidros, Ahmed M. Tarawah, Waheed A. Turkistani, Mohamed A. Zolaly, Abdulhadi M. Habib

51. Reference centres and networking. Experiences from the region: Pakistan  
    Mohammed Adil Akhter

**Session 6: Emerging issues in patient care**

52. Patient’s rights: legislation globally and in the region  
    Mahmoud Hadipour Dehshai, Mehdi Tabrizi Namini
Challenges of migrations in the Middle East region
Walid Slim, Galev Aleksandar

Session 7: New approaches and advances for care and cure
Clinical outcomes of gene therapy with BB305 lentiviral vector for sickle cell disease and β-thalassaemia
Jean-Antoine Ribeil, Marina Cavazzana, Fabien Touzet, Emmanuel Payen, Bénédicte Neven, Francois Lefrere, Felipe Suarez, Elisa Magrin, Yves Beuzard, Resy Cavaltesco, Stany Chretien, Philippe Bourget, Fabrice Monpoux, Corinne Pondarré, Pablo Bartolucci, Manfred Schmidt, Christof von Kalle, Frans A. Kuyers, Laura Sander, Sandeep Soni, Michaela Semeraro, Wassim El Nemer, Olivier Hermine, Mariane De Montalembert, Stéphane Blanche, Salima Hacen-Bey-Abina, Philippe Leboulch

Session 8: Ongoing concerns globally and in the region
Blood and blood products: adequacy and safety
Hassan Abolghasemi, Vahid Abolghasemi
Approach to haemovigilance in transfusion dependent patients
Salwa Hindawi, Maha Badawi
Medicinal products; accessibility and availability; experience of Egypt
Amal El-Beshlawy
The use of safe and effective medicinal products in the region
Mahmoud Hadipour Dehshal

Posters
Blood transfusion - Adequacy and safety
Assessment of a cohort of β-thalassaemia patients: new challenges
Mohamed Bradai, Nouria Benmouaffek

Bone Disease
Evaluation of bone mineral density in patients with haemoglobin H disease
Mehran Karimi, Tarehe Rezei, Sezaneh Haghpanah, Shirin Parand, Hossein Moravej, Mohammad Hossein Dabbaghmanesh, Gholamhossein Ranjbar Omrani, Zohreh Zahedi
Which pamidronate protocol is the best for treating osteoporosis in β-thalassaemia major?
Mandana Zafari, Mehrnoush Kowsariyan
Osteoporosis among β-thalassaemia patients in the West Bank of Palestine
Bashar Karmi, Akram Kharroubi, Walaa Shamasna, Elias Saba

Diagnostic and Monitoring Techniques
Evaluation of renal iron deposition using T2* magnetic resonance imaging in thalassaemia (Large Cohort Study)
Shirkavand Afshar, Mokhtan Hesari Parisa, Akhlaghpour Shahram, Mansoori Bahar, Azarkeivan Azita, Hashernieh Moshgan
Serum ferritin level as a surrogate to liver iron concentration and cardiac T2* for determination of hepatic and cardiac iron overload in patients with thalassaemia major
Hassan M. Moukhadder, Rayan Bou Fakhredin, Joseph Roumi, Hassan Beydoun, Therese Abou Nasr, Suzanne Koussa, Ali T. Taher
Determination of cardiac function by serum ferritin level, cardiac T2*, and liver iron concentration in patients with thalassaemia major
Hassan M. Moukhadder, Joseph Roumi, Rayan Bou Fakhredin, Hassan Beydoun, Therese Abou Nasr, Suzanne Koussa, Ali T. Taher

Endocrine Complications
The Saudi experience on the effects of endocrine complications and its morbidity in thalassaemia
Soad Khalil Al Jaouni
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>78</td>
<td>The association of pancreatic MRI R2* with fasting and 2-hour postprandial blood glucose among thalassaemia major patients in Indonesia</td>
<td>Pustika Amalia Wahidiat, Siti Ayu Putriasih, Nitish Basant Adriani</td>
</tr>
<tr>
<td>78</td>
<td>Epidemiology and Prevention</td>
<td></td>
</tr>
<tr>
<td>78</td>
<td>Carrier frequency of α-thalassaemia mutations among newborns in Northern Iran</td>
<td>Mohammad Reza Mahdavi, Mehrnoush Kosaryan, Hossein Karami, Merhad Mahdavi, Hossein Jaladi, Payam Roshan</td>
</tr>
<tr>
<td>79</td>
<td>Non-invasive prenatal diagnosis of β-thalassaemia by detection of the cell free fetal DNA in maternal circulation; a systematic review study and meta-analysis</td>
<td>Mandana Zafari, Mehrnoush Kowsaryan, Pooria Gill, Abbass Alipour, Mohammad Reza Shiran, Hossein Jalali, Ali Banihashemi, Fatemeh Fatahi</td>
</tr>
<tr>
<td>79</td>
<td>High resolution melting analysis for non-invasive prenatal diagnosis of IVS-II-1 (G-A) fetal DNA in minor β-thalassaemia mothers</td>
<td>Mandana Zafari, Pooia Gill, Mehrnoush Kowsaryan, Abbass Alipour, Ali Banihashemi</td>
</tr>
<tr>
<td>79</td>
<td>National Programme for Blood Genetic Disorders – Revisited</td>
<td>Mohsen A.F.El-Hazmi</td>
</tr>
<tr>
<td>80</td>
<td>Prenatal genetic implantation as a possible alternative to elective abortion: the Lebanese experience</td>
<td>Rayan Bou Fakhredin, Hassan M. Moukhaddar, Joseph Roumi, Rita Aoun, Therese Abou Nasr, Ali T. Taher</td>
</tr>
<tr>
<td>80</td>
<td>Impact of prenatal diagnosis of thalassaemia on disease prevention: a single-center experience from Lebanon</td>
<td>Michele Abi Saad, Hassan M. Moukhaddar, Rita Aoun, Joseph Roumi, Rayan Bou Fakhredin, Sanaa Aoun, Ali T. Taher</td>
</tr>
<tr>
<td>80</td>
<td>Insight into the incidence and inheritance pattern of β-thalassaemia in Lebanon</td>
<td>Joseph Roumi, Hassan M. Moukhaddar, Rayan Bou Fakhredin, Rita Aoun, Ali T. Taher</td>
</tr>
<tr>
<td>81</td>
<td>Epidemiology of β-thalassaemia major in the Rabat Reference Center</td>
<td>Mohammed Khattab, Zineb Isfaoun, Maria EL Kababri, Amina Kili, Mohammed El Khorassani, Laila Hessissen</td>
</tr>
<tr>
<td>81</td>
<td>Fertility and Pregnancy</td>
<td></td>
</tr>
<tr>
<td>81</td>
<td>Evaluation of marriage and childbirth in patients with non-transfusion dependent β-thalassaemia major at Thalassemia Research Center of Sari, Iran</td>
<td>Mandana Zafari, Mehrnoush Kowsariyan</td>
</tr>
<tr>
<td>81</td>
<td>Gene Regulation and Therapy</td>
<td></td>
</tr>
<tr>
<td>81</td>
<td>β-globin gene cluster haplotypes of Hb D-Los Angeles in Mazandaran Province, Iran</td>
<td>Mohammad Reza Mahdavi, Hossein Jalali, Mehrnoush Kosaryan, Payam Roshan, Mehrad Mahdavi</td>
</tr>
<tr>
<td>82</td>
<td>β globin gene haplotypes associated with haemoglobin D-Punjab in Northern Iran</td>
<td>Jalali Hossein, Mahdavi Mohammad-Reza, Kosaryan Mehrnohtsh, Karami Hossein, Roshan Payam, Maddahian Fatemeh</td>
</tr>
<tr>
<td>82</td>
<td>Heart and Vascular Abnormalities</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>Prevalence of pulmonary hypertension in patients with thalassaemia intermedia; a single center experience</td>
<td>Zahra Badie, Hassan Mottaghi Moghaddam, Hamid Farhangi, Reza Shakeri</td>
</tr>
<tr>
<td>82</td>
<td>Kidney injury molecule-1 and heart-type fatty acid binding protein as novel early markers of proximal and distal renal tubular dysfunction in children with β-thalassaemia major</td>
<td>Laila M Sherief,Osama R El-Safy, Amal Zidan, Doaa M Youssef, Manar El-sayed</td>
</tr>
<tr>
<td>83</td>
<td>The relationship between serum vascular endothelial growth factor and β-thalassaemia major</td>
<td>Farzane Farokhi, Javad Razaviyani, Mehrmoush Kosaryan, Mostafa Roudbari, Samira Esmaili Reykande, Aily Aliasgharian, Maryam Dehghani</td>
</tr>
<tr>
<td>83</td>
<td>Digital thermography and vascular involvement in thalassaemia intermedia</td>
<td>Marvan Refaat, Patrick Zakka, Mostafa Hotait, Samir Arnaout, Hussein Isma'a, Ali Taher</td>
</tr>
<tr>
<td>83</td>
<td>Hepatological Complications</td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>Decrease of hepatitis C burden in patients with transfusion dependent β-thalassaemia major, Thalassemia Research Center, 1995-2014</td>
<td>Mehrmoush Kosaryan, Aily Aliasgharian</td>
</tr>
</tbody>
</table>
84  Iron liver toxicity presenting as hepatic nodule in major β-thalassaemia patient: a case report
Anna Mira Lubis

Haematopoietic stem cells transplantation
84  A retrospective long-term study from allogeneic haematopoietic stem cells transplantation in major β-thalassaemia: the Algerian experience
Malek Benakli, Redhouane Ahmed Nacer, Rachida Belhadj, Farth Mehdid, Farida Tensaout, Nadia Rahmoune, Dina Al Ouali, Mounira Baazizi, Harane Bouarab, Sara Zerkout, Nadia Boukhenfout, Rose-Marie Hamlaoui

Iron overload and management
85  Safety of deferasirox in β-thalassaemia patients with serum ferritin less than 1000
Mehran Karimi, Zahra Barati Shourjeh, Sezaneh Haghpanah, Zohre Zahedi
85  Efficacy of oral deferasirox by twice-daily dosing in patients with transfusion-dependent β-thalassaemia
Ebrahim Salehifar, Hosein Karami, Mehmoood Kosaryan, Hosein Masoudi, Aily Alasgharian, Masoumeh Mousavi, Razieh Avan
85  In vivo iron-chelating activity and phenolic profiles of the Angel’s Wings mushroom, Pleurotus porrigens (Higher Basidiomycetes)
Masoumeh Khalili, Mohammad Ali Ebrahimzadeh, Mehroush Kosaryan
86  Iron chelation and liver disease healing activity of edible mushroom (Cantarellus cibarius), in vitro and in vivo assays
Masoumeh Khalili, Mohammad Ali Ebrahimzadeh, Mehroush Kosaryan, Ali Abbasid, Mohammad Azadbakht
86  Efficacy of three iron-chelating agents in thalassaemia patients from our practice
Joseph Roumi, Rayan Bou Fakhredin, Hassan M. Moukhadder, Hassan Beydoun, Therese Abou Nasr, Suzanne Koussa, Ali T. Taher
86  Urinary iron examination to evaluate iron overload in children with thalassaemia major
Pustika Amalia Wahidiyat, Ellen Wijaya
87  Combination of deferoxamine/deferiprone in improving cardiac, liver and pancreatic T2* in twins with β-thalassaemia major and severe iron overload: a case report
Ludi Dhyani Rahmartani, Pustika Amalia Wahidiat, Teny Tjiya Sari
87  Is there a difference in neutrophil phagocytosis among different iron chelators?

Miscellaneous
87  Refractive errors and ocular biometry components in thalassaemia major patients
Samira Heydarian, Reza Jafari, Hosein Karami
88  Ocular abnormalities in multi-transfused β-thalassaemia patients
Reza Jafari, Samira Heydarian, Hosein Karami, Mohammad Momeni Shektai, Kiumars Noruzpour Dailami, Ahmad Ahmazadeh Amiri, Majid Reza Sheikh Rezaee, Asad Allah Farrokh Far
88  Does β-thalassaemia increase the incidence of bells palsy?
Shahrzad S. Al-Jabro
88  Thalassaemia, new challenges/Palestine
Bashar Karmi

New Developments in Thalassaemia
89  Potential effects of silmyarin and its flavonolignan components in patients with β-thalassaemia major: a comprehensive review in 2015
Hadi Darvishi Khezri, Ebrahim Salehifar, Mehroush Kosaryan, Aily Alasgharian, Hossein Jalali, Arash Hadian Amree
89  Luspatercept decreases transfusion burden and liver iron concentration in regularly transfused adults with β-thalassaemia
90  Luspatercept increases haemoglobin and improves quality of life in non-transfusion dependent adults with β-thalassaemia
Non transfusion-dependent thalassaemia

90 Utility of serum ferritin levels between 300 and 800 ng/mL in clinical decision making in non transfusion-dependent thalassaemia when magnetic resonance imaging for liver iron concentration measurement is not available
Antoine N. Saliba, Khaled M. Musallam, Maria D. Cappellini, Vip Viprakasit, Shahina Daar, Hassan M. Moukhadder, Ali T. Taher

91 ARAP-536 (murine analog of ace-536/luspatercept) inhibits smad2/3 signaling and promotes erythroid differentiation by restoring gata-1 function in a murine model of β-thalassaemia
Pedro Martinez, Manoj Bhasin, Robert Li, Scott Pearsall, Ravindra Kumar, Rajasekhar Suragani

91 Qualitative research on the obstacles in marriage and reproductive process of people with transfusion dependent thalassaemia
Sachiko Hosoya, Gholam Reza Jamali, Mohsen Shahrnari

91 Knowledge attitude and practices among patients on treatment of thalassaemia in Maldives
Fathmath Jeehan Saleem

91 Attributional styles in adolescents with transfusion-dependent thalassaemia
Lerlugsn Suwanthol, Tuangrath Sangpaypan, Phetcharat Naknum, Kleebasai Sanpakit

Quality Care for Quality of Life

92 Multifaceted approach to thalassaemia care and management – Our experience and lessons learned
Shashikant Patil, Rajendra Kuikarni, Vaishali Kale, Sreval Patil, Nandkishor Tated, Atul Jain

93 Presentation of thalassaemia ward in East medical special center in Tehran and clinical challenges in management of thalassaemic patients in all fields
M. Sabzechian, R. Fallah, M. Gholami

93 Effect of deferasirox use on the educational status of patients with thalassaemia: a 20-year, single-center experience
Rayan Bou Fakhredin, Joseph Roumi, Josephine Ajouz, Hassan M. Moukhadder, Rita Aoun, Suzanne Koussa, Ali T. Taher

93 Development of patient-reported outcomes symptom measure for patients with non-transfusion-dependent thalassaemia (NTDT-PRO©)
Ali Taher*, Antoine Saliba, Antonis Kattamis, Richard Ward, Gale Harding, Xiaohan Hu, Dalia Mahmoud

Sickle Cell Disease

94 Clinical and haematological profiles among Bahraini children with sickle cell disease
Husain AlMuhammad

94 Association of methylenetetrahydrofolate reductase A1298C and C677T polymorphisms with vaso-occlusive crisis in sickle cell disease
Ahmed A. Raouf, Mona M. Hamdy, Ahmed M. Badr, Osama F. Shalaan, Moustafa A. Sakr, Abdel Rahman A. Abdel Rahman

95 Clinical presentation of childhood sickle cell disease and its correlation with disease prognosis: a single centre study
Abdulrahman Al Aslant, Nasr Jastani, Sameera Al Afghani, Muneer H. Al Baghi, Zakia Obourallah, Ahmed M. Al-Suliman, Mohammed K Al-Abdulla

95 The outcome of preoperative transfusion guideline on sickle cell disease patients at King Fahd Hospital-Jeddah
Sameera M.R. Felemban, Rekha Bajoria, Amani Alsawaf, Ratna Chatterjee, Abdelrahman A. Qadi

95 Demands and challenges for patients with sickle cell disease requiring haematopoietic stem cell transplantation in Saudi Arabia
Abdulrahman Alsultan, Wasil Jastani, Sameera Al Afghani, Muneer H. Al Baghi, Zakia Obourallah, Ahmed M. Al-Suliman, Mohammed K Al-Abdulla

96 Hydroxyurea, an effective therapy to avoid splenectomy in sickle cell disease and thalassaemia: single institute experience in Saudi Arabia
Saad Khalil Al Jawi

96 My personal journey through hydroxyurea therapy in sickle cell disease during pregnancy and lactation
Aishath Shifneez Shakir